Ana Lisa Basquiera

Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine | Blood | American Society of Hematology ashpublications.org/blood/article/…

A new @GETH_info collaborative paper with #ICOnic @HematoRules participation Great Job!!! Congrats everyone! @ICO_oncologia @sehh_es @SEHHJoven sciencedirect.com/science/articl…

🩸 ¿Aféresis o punción? Si el Registro Nacional te convoca para donar médula ósea, podés elegir el método con acompañamiento médico. Recordá que inscribirte es un compromiso a largo plazo 🧑🏻➡️👨🏻‍🦱➡️👴🏻 📧 Actualizá tus datos enviando en correo a donantes@incucai.gov.ar para que podamos contactarte, en caso de que resultes compatible. #DonáVidaEnVida

What is the optimal GVHD prophylaxis in myelofibrosis? - It's complicated... Our study on ATG vs PTCY in matched transplants @AjHematology: onlinelibrary.wiley.com/doi/10.1002/aj… Congrats to the collaboration team!

News for transplant physicians. Donor change in second salvage transplantation after graft failure following allogeneic stem cell transplantation may be critical for engraftment and survival. haematologica.org/article/view/1…

La SEHH destaca la importancia de detectar la anemia a tiempo en el Día Mundial de Concienciación sobre esta enfermedad sehh.es/noticias/10135… via @EMAILiT

Gracias @basquiera por recibirnos!!!! Generosidad enorme. Gran experiencia con un excelente equipo de trabajo @Carlitocha

At the GVHD Alliance Reception last night, Dr. Shernan Holtan presented Dr. Corey Cutler with the Lukas D. Wartman Award! This award recognizes Dr. Cutler’s dedication to improving patient outcomes and treating GVHD. #Tandem26 @sghmd @DrCCutler

Suggested Best Practices for Dexamethasone in Plasma Cell Disorders Recommendation @RahulBanerjeeMD

Early View | Haematologica haematologica.org/newsletter/v1/…

El GEM-PETHEMA presenta la Guía de Mieloma Múltiple 2025: diagnóstico, estratificación del riesgo y tratamientos actualizados, incluyendo nuevas terapias e IMR. fundacionpethema.es/sites/default/… Un referente para la práctica clínica en hematología. #MM #GEMPETHEMA #Hematología

Just out! All you need to know about Smoldering Mulitple Myeloma. Our comprehensive Review in @NatRevClinOncol Bookmark! @ZanwarSaurabh @myelomaMD @MayoCancerCare @SpringerNature For limited time free access: nam12.safelinks.protection.outlook.com/?url=https%3A%…

📢 Nueva publicación estudio @geltamo en British Journal of Haematology: Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting. @asernapareja @ab_pau 🔗 doi.org/10.1111/bjh.70…

Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure @gloria_iacoboni link.springer.com/content/pdf/10…

How I manage mycosis fungoides and Sézary syndrome: Current controversies and unmet needs. British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-Analysis @ASTCT_Journal astctjournal.org/article/S2666-…

Your paper isn't getting rejected because your research is bad. Here's what actually gets papers rejected ⤵️ Your literature review is outdated Copying and paraphrasing old reviews? Editors spot this instantly. They want fresh citations from the last 2-3 years. You're working on exhausted topics When 1000+ papers already exist on your topic, your work needs something genuinely new. First movers get published. Fast followers get cited. Your sample is too small or convenient Student samples? Snowball sampling? Convenient sampling? Desk rejection. Premier journals demand robust methodology. No theoretical contribution Data without theory = rejection. Your findings need to advance how we understand the phenomenon. You're defending instead of revising Getting a revise-and-resubmit is rare (5-7% of submissions). Treat reviewer comments like gold. Implement them. Don't defend. The 3 things that changed my acceptance rate: → Mixed methods over single studies → Multiple experiments in one paper → Including co-authors with complementary expertise Publishing isn't about being perfect. It's about being strategic! What's been your biggest publishing challenge? 1/6

👵🏼 Alo‑HCT en pacientes mayores: experiencia GETH‑TC. Liderado por Sara Fernández‑Luis, de @HUnivValdecilla, abundando en el debate científico sobre mejora de los resultados del #TPH en esta población. journals.lww.com/transplantjour…

Humbled to share that our work with the GATMO-TC group is now Online First. Sincere thanks to all collaborators across centers for the collective effort, and to our external mentors for their guidance and generosity. doi.org/10.1016/j.jtct…

May-Hegglin Anomaly >> Pay attention to neutrophil inclusions in pediatric patients with thrombocytopenia | ASH Image Bank | American Society of Hematology imagebank.hematology.org/image/62774/pa… #ASHImageBank